» Articles » PMID: 32282398

A Retrospective Study of Treatment Outcomes and Prognostic Factors of Intense Pulsed Light Therapy Combined With Meibomian Gland Expression in Patients With Meibomian Gland Dysfunction

Overview
Specialty Ophthalmology
Date 2020 Apr 14
PMID 32282398
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

Objectives: To evaluate clinical changes after intense pulsed light and meibomian gland expression (IPL/MGX) treatment in meibomian gland dysfunction (MGD) patients, and to identify ideal candidates, and the therapeutic window, for IPL/MGX.

Methods: This retrospective study reviewed the medical records of 44 MGD patients (44 eyes). The IPL/MGX treatment was applied on the eyelids three times at intervals of 4 weeks. Age, sex, relevant ocular history, Standard Patient Evaluation of Eye Dryness (SPEED), Ocular Surface Disease Index (OSDI), tear break-up time (TBUT), corneal fluorescein staining score (CFSS), meiboscore, meibomian gland loss score (MGLS), meibomian glands yielding secretion score (MGYSS), meibomian glands yielding clear secretion (MGYCS), and meibomian glands yielding liquid secretion (MGYLS) were analyzed.

Results: Standard Patient Evaluation of Eye Dryness, OSDI, TBUT, CFSS, MGYSS, MGYLS, and MGYCS were significantly improved after three IPL/MGX treatments, but the meiboscore and MGLS remained unchanged. In patients who had better treatment outcomes (improvement in MGYSS >7), younger age (36.0, 22.5 vs. 53.0, 25.0 years; P=0.012), a longer TBUT (8.0, 4.5 vs. 6.0, 3.0 sec; P=0.010), better meiboscore (1.0, 0.5 vs. 2.0, 1.0; P=0.012), and less gland loss (19.8%, 20.3% vs. 41.1%, 30.2%; P=0.008) before IPL/MGX were noted. Sex, relevant ocular history, SPEED, OSDI, MGYSS, MGYLS, and MGYCS before IPL/MGX showed no significant differences between patients with an improvement in MGYSS >7 versus those with an improvement of ≤7. Meibomian glands yielding secretion score changes in patients who had a meiboscore of 0 to 1 and MGYSS of 0 before IPL/MGX (12.0, 10.0) were significantly higher than those who had a meiboscore of 2 to 3 and MGYSS of 0 (6.5, 9.3; P=0.031), or a meiboscore of 0 to 1 and MGYSS >0 (5.0, 11.5; P=0.041).

Conclusions: Improved dry eye symptoms, TBUT, corneal staining, and meibomian gland secretion were observed in MGD patients after IPL/MGX. Patients in the early stages of MGD maybe benefited most from IPL/MGX treatment.

Citing Articles

Comparison of Intense Pulsed Light Treatments including Upper Lid or Lateral Canthus in Patients of Meibomian Gland Dysfunction.

Min J, Jun I, Kim T, Arita R, Seo K J Clin Med. 2024; 13(12).

PMID: 38930110 PMC: 11204452. DOI: 10.3390/jcm13123581.


Current application of intense pulsed light for the management of dry eye disease: A systematic review and meta-analysis.

Pratomo T, Zaifar A, Wibowo N, Suryono A, Aziza Y Indian J Ophthalmol. 2023; 72(Suppl 2):S183-S190.

PMID: 38146980 PMC: 11624638. DOI: 10.4103/IJO.IJO_671_23.


Intense pulsed-light treatment improves objective optical quality in patients with meibomian gland dysfunction.

Whang W, Yun J, Koh K BMC Ophthalmol. 2023; 23(1):191.

PMID: 37118666 PMC: 10148435. DOI: 10.1186/s12886-023-02939-9.


Comparison of clinical outcomes between intense pulsed light therapy using two different filters in meibomian gland dysfunction: prospective randomized study.

Jang J, Lee K, Nam S, Kim J, Kim J, Tchah H Sci Rep. 2023; 13(1):6700.

PMID: 37095152 PMC: 10126147. DOI: 10.1038/s41598-023-33526-z.


Efficacy of intense pulsed light therapy on signs and symptoms of dry eye disease: A meta-analysis and systematic review.

Qin G, Chen J, Li L, Zhang Q, Xu L, Yu S Indian J Ophthalmol. 2023; 71(4):1316-1325.

PMID: 37026263 PMC: 10276661. DOI: 10.4103/IJO.IJO_2987_22.